In December 2019 the novel coronavirus, SARS‐CoV‐2, responsible for the COVID‐19 was identified. This rapidly led to spread throughout the world and the declaration of a pandemic by the World Health Organisation. Vaccine development programmes have led to several different pharmaceutical company vaccines in clinical trials, with reported response rates in the healthy volunteer population of between 70-94%.
As haematologists, we rarely treat patients of the demographic included in vaccine clinical trials. Vaccination of our patient population is complex. Due to the severity of SARS-CoV-2 infection it is likely that the majority of the patient population will undergo vaccination.
There is a reporting bias within the literature favoured towards positive events, e.g. relapse AA, thus a wider review for patients undergoing vaccination for SARS-CoV-2 with PNH and aplastic anaemia is proposed. You are kindly invited to join this study and contribute your patient data.
Patients are eligible if:
- they have been diagnosed with aplastic anaemia and/or PNH, irrespective of vaccination status;
- they have not yet undergone a bone marrow transplant.
If you are interested to participate in this study, we would be very grateful if you could indicate your interest to Anne Lippinkhof (email@example.com) before April 1st, 2021.
Morag Griffin – Principal Investigator
Peter Hillmen – International PNH interest Group and PNH registry Chair
Per Ljungman – Study Investigator
Anne Lippinkhof – SAAWP Study Coordinator
Antonio Risitano – SAAWP Secretary
Régis Peffault de Latour – SAAWP Chair